ORION CORPORATION STOCK EXCHANGE RELEASE 28 NOVEMBER 2019 at 10.20 EET
Orion Corporation: Disclosure under chapter 9, section 10 of the Securities Market Act: The total share of voting rights of Orion shares owned by Maa- ja vesitekniikan tuki ry and a company controlled by it, Tukinvest Oy, has exceeded 5%
Orion Corporation has on 28 November 2019 received from Maa- ja vesitekniikan tuki ry a notification under Chapter 9, Section 5 of the Securities Markets Act, according to which the total share of voting rights of the Orion shares owned by Maa- ja vesitekniikan tuki ry and a company controlled by it, Tukinvest Oy, has exceeded 5% in consequence of the share conversion under the Articles of Association of Orion Corporation executed on 28 November 2019.
According to the notification, the total share of voting rights of Maa- ja vesitekniikan tuki ry and Tukinvest Oy is 5.01%.
Total positions of Maa- ja vesitekniikan tuki ry and Tukinvest Oy:
| % of voting rights (a) | % of votes through financial instruments (b) | Total of both in % (a+b) | Total number of voting rights of issuer | |
| Resulting situation on the date on which threshold was crossed or reached | 5.01% | - | 5.01% | 832,276,561 |
| Position of previous notification (if applicable) | - | - | - | - |
| % of shares (a) | % of shares through financial instruments (b) | Total of both in % (a+b) | Total number of shares of issuer | |
| Resulting situation on the date on which threshold was crossed or reached | 1.47% | - | 1.47% | 141,257,828 |
| Position of previous notification (if applicable) | - | - | - | - |
Notified details of the resulting situation on the date on which the threshold was crossed or reached::
| Class/type of shares ISIN code | Number of voting rights | % of voting rights | ||
| Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | |
| A share, FI0009014369 | 20,697,200 | 20,970,000 | 2.49% | 2.52% |
| B share, FI0009014377 | - | - | - | - |
| TOTAL | 41,667,200 | 5.01% | ||
| Class/type of shares ISIN code | Number of shares | % of shares | ||
| Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | |
| A share, FI0009014369 | 1,034,860 | 1,048,500 | 0.73% | 0.74% |
| B share, FI0009014377 | - | - | - | - |
| TOTAL | 2,083,360 | 1.47% | ||
Information in relation to person subject to the notification obligation:
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity:
| Name | % of voting rights | % of voting rights through financial instruments | Total of both |
| Maa- ja vesitekniikan tuki ry | 2.49% | - | 2.49% |
| Tukinvest Oy | 2.52% | - | 2.52% |
| Name | % of shares | % of shares through financial instruments | Total of both |
| Maa- ja vesitekniikan tuki ry | 0.73% | - | 0.73% |
| Tukinvest Oy | 0.74% | - | 0.74% |
Orion Corporation
| Jari Karlson CFO | Olli Huotari SVP, Corporate Functions |
Contact person:
Tuukka Hirvonen, Investor Relations, tel. +358 010 426 2721
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orion.fi
Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases for which Orion develops inhaled Easyhaler pulmonary drugs. Orion's net sales in 2018 amounted to EUR 977 million and the company had about 3,200 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.
